Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 936-941

  Chen, Pei Lin ^a   Easton, Alexander S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Apoptosis; Fas ligand; TRAIL; Vascular endothelium

Indexed keywords

BROXURIDINE; CASPASE 3; CASPASE INHIBITOR; FAS LIGAND; MATRIGEL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BRAIN BLOOD VESSEL; BRAIN DEVELOPMENT; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; NEURAL TUBE; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

APOPTOSIS; BRAIN; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FAS LIGAND PROTEIN; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 72949111392     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.11.168     Document Type: Article

References (26)

1. Beck H., and Plate K.H. Angiogenesis after cerebral ischemia. Acta Neuropathol. 117 (2009) 481-496
2. Bogler O., and Mikkelsen T. Angiogenesis and apoptosis in glioma: two arenas for promising new therapies. J. Cell. Biochem. 96 (2005) 16-24
3. Kirk S., Frank J.A., and Karlik S. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?. J. Neurol. Sci. 217 (2004) 125-130
4. Degli-Esposti M. To die or not to die-the quest of the TRAIL receptors. J. Leukoc. Biol. 65 (1999) 535-542
5. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
6. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
7. Secchiero P., Gonelli A., Carnevale E., Corallini F., Rizzardi C., Zacchigna S., Melato M., and Zauli G. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 6 (2004) 364-373
8. Cantarella G., Risuglia N., Dell'eva R., Lempereur L., Albini A., Pennisi G., Scoto G.M., Noonan D.N., and Bernardini R. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br. J. Cancer 94 (2006) 1428-1435
9. Weksler B.B., Subileau E.A., Perriere N., Charneau P., Holloway K., Leveque M., Tricoire-Leignel H., Nicotra A., Bourdoulous S., Turowski P., Male D.K., Roux F., Greenwood J., Romero I.A., and Couraud P.O. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19 (2005) 1872-1874
10. Alladina S.J., Song J.H., Davidge S.T., Hao C., and Easton A.S. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J. Vasc. Res. 42 (2005) 337-347
11. Chen P.L., and Easton A.S. Apoptotic phenotype alters the capacity of tumor necrosis factor-related apoptosis-inducing ligand to induce human vascular endothelial activation. J. Vasc. Res. 45 (2008) 111-122
12. Liang C.C., Park A.Y., and Guan J.L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2 (2007) 329-333
13. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
14. Zauli G., and Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 17 (2006) 245-257
15. Gochuico B.R., Zhang J., Ma B.Y., Marshak-Rothstein A., and Fine A. TRAIL expression in vascular smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 278 (2000) L1045-L1050
16. Zauli G., Pandolfi A., Gonelli A., Di Pietro R., Guarnieri S., Ciabattoni G., Rana R., Vitale M., and Secchiero P. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ. Res. 92 (2003) 732-740
17. Smyth M.J., Takeda K., Hayakawa Y., Peschon J.J., van den Brink M.R., and Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 18 (2003) 1-6
18. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., and Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
19. McGonigle J.S., Giachelli C.M., and Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 12 (2009) 35-46
20. Shankar S., Ganapathy S., and Srivastava R.K. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin. Cancer Res. 14 (2008) 6855-6866
21. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., and Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6 (2000) 564-567
22. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., and Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 (2001) 383-385
23. Wosik K., Biernacki K., Khouzam M.P., and Prat A. Death receptor expression and function at the human blood brain barrier. J. Neurol. Sci. 259 (2007) 53-60
24. Pritzker L.B., Scatena M., and Giachelli C.M. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell 15 (2004) 2834-2841
25. Benndorf R., Boger R.H., Ergun S., Steenpass A., and Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ. Res. 93 (2003) 438-447
26. Ashton A.W., and Ware J.A. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ. Res. 95 (2004) 372-379